P. Rijal

A locally administered single cycle influenza vaccine expressing a non-fusogenic stabilised haemagglutinin stimulates strong T-cell and neutralising antibody immunity

This paper develops a single-cycle influenza vaccine, CLEARFLU, that induces neutralising antibodies to haemagglutinin and T-cell responses, offering broad and strain-specific protection.

Antigenic characterisation of human monoclonal antibodies for therapeutic use against H7N9 avian influenza virus

This study characterizes human monoclonal antibodies against H7N9 avian influenza virus, identifies key epitopes, and evaluates escape mutants' impact on viral fitness and immune evasion.

Low dose pig anti-influenza virus monoclonal antibodies reduce lung pathology but do not prevent virus shedding

This study shows that high-dose pig monoclonal antibodies reduce lung pathology and virus load but not nasal shedding, suggesting lower doses may suffice for disease severity reduction.

Spatial, temporal and molecular dynamics of swine influenza virus-specific CD8 tissue resident memory T cells.

The paper identifies and characterizes influenza NP-specific CD8 T cells in porcine tissues, showing their persistence and gene expression changes in the lung.

Neutralization of SARS-CoV-2 by destruction of the prefusion Spike

This paper identifies CR3022 as a monoclonal antibody that neutralizes SARS-CoV-2 by destroying its prefusion Spike conformation, suggesting therapeutic potential.

A COVID-19 vaccine candidate using SpyCatcher multimerization of the SARS-CoV-2 spike protein receptor-binding domain induces potent neutralising antibody responses

This study develops a vaccine candidate using SpyCatcher technology to display the SARS-CoV-2 RBD, showing strong neutralizing antibody responses in mice and pigs.

Plasmablast-derived antibody response to acute SARS-CoV-2 infection in humans

This study analyzes plasmablast-derived antibodies in three COVID-19 patients, identifying neutralizing antibodies and cross-reactivity with other betacoronaviruses.

Protective porcine influenza virus-specific monoclonal antibodies recognize similar haemagglutinin epitopes as humans

This study generates pig-specific monoclonal antibodies against H1N1pdm09 influenza virus that target human-like HA epitopes and reduce disease severity in pigs.

A novel biparatopic antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy

The paper develops a biparatopic antibody-ACE2 fusion (89C8-ACE2) that effectively blocks SARS-CoV-2 infection in vitro and neutralizes authentic virus at low nanomolar concentrations.

Structural basis for the neutralization of SARS-CoV-2 by an antibody from a convalescent patient

This paper identifies an antibody, EY6A, from a convalescent patient that neutralizes SARS-CoV-2 and cross-reacts with SARS-CoV-1 by binding a conserved epitope on the Spike protein.

Establishment of a pig influenza challenge model for evaluation of monoclonal antibody delivery platforms

This study establishes a pig influenza model to evaluate monoclonal antibody efficacy against H1N1, showing dose-dependent reduction in viral load and lung pathology.

Semaphorin 3A induces cytoskeletal paralysis in tumor-specific CD8+ T cells

This study shows Sema3A inhibits tumor-specific CD8+ T cell function by inducing cytoskeletal paralysis via NRP1 in the tumor microenvironment.

Broadly inhibiting anti-neuraminidase monoclonal antibodies induced by trivalent influenza vaccine and H7N9 infection in humans

This study identifies broadly reactive human monoclonal antibodies against N1 neuraminidase from vaccination and H7N9 infection, showing cross-inhibition of diverse N1 NAs and protective efficacy in mice.

A single cycle influenza virus coated in H7 hemagglutinin provides heterotypic protection and neutralising antibody responses to both glycoproteins.

This study shows that a single-cycle influenza virus coated with H7 hemagglutinin induces heterotypic protection and neutralizing antibodies against multiple H7 strains.